Exhibit 99.01
| Press Release |  |
| www.shire.com |
Notification of major interests in shares
November 13, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG)
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | Shire plc |
| 2. Reason for the notification | State Yes/No |
| An acquisition or disposal of voting rights | Yes |
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | No |
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | Yes |
| An event changing the breakdown of voting rights | No |
| Other (please specify): | No |
| 3. Full name of person(s) subject to the notification obligation: | BlackRock Inc. |
| 4. Full name of shareholder(s) (if different from 3.): | N/A |
5. Date of the transaction (and date on which the threshold is crossed or reached if different): | 8 November 2013 |
| 6. Date on which issuer notified: | 12 November 2013 |
| 7. Threshold(s) that is/are crossed or reached: | Below 10% |
| 8. Notified details: | |||||||
A: Voting rights attached to shares |
Class/type of shares if possible using the ISIN CODE | Situation previous to the Triggering transaction | Resulting situation after the triggering transaction | ||||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights | ||||
| Direct | Direct | Indirect | Direct | Indirect | ||||
JE00B2QKY057 | 54,260,621 | 54,260,621 | N/A | N/A | 54,247,601 | N/A | 9.79% | |
B: Qualifying Financial Instruments | ||||
Resulting situation after the triggering transaction | ||||
Type of financial instrument | Expiration date | Exercise/Conversion Period/ Date | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
| N/A | N/A | N/A | N/A | N/A |
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financial instrument | Exercise price | Expiration date | Exercise/ Conversion period | Number of voting rights instrument refers to | % of voting rights | |
CFD | N/A | N/A | N/A | 1,006,840 | Nominal | Delta |
0.18% | 0.18% | |||||
| Total (A+B+C) | |
| Number of voting rights | % of voting rights |
| 55,254,441 | 9.98% |
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: |
| BlackRock Investment Management (UK) Limited – 55,254,441 (9.98%) |
Proxy Voting: 10. Name of the proxy holder: | N/A |
| 11. Number of voting rights proxy holder will cease to hold: | N/A |
| 12. Date on which proxy holder will cease to hold voting rights: | N/A |
| 13. Additional information: | BlackRock Regulatory Threshold Reporting Team |
| 14. Contact name: | Duncan Murray |
| 15. Contact telephone number: | 020 7743 3334 |
Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, 01256 894746
For further information please contact:
| Investor Relations | ||
| Eric Rojas | erojas@shire.com | +1 781 482 0999 |
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
www.shire.com